Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Asthma patients are more likely to have an asthma attack during winter
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
Subscribe To Our Newsletter & Stay Updated
